Investor Relations



We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in seven FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.




  • Apr 08

    Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)
  • Apr 06

    Regeneron Finalizes Praluent® (alirocumab) Restructuring and Updates Accounting Presentation


  • 2020 Annual Meeting of Shareholders
    Jun 12
    10:30 AM EDT
    Jun 12, 2020 | 10:30 AM EDT

  • Regeneron Pharmaceuticals Q1 2020 Earnings Conference Call
    May 5
    8:30 AM EDT
    May 5, 2020 | 8:30 AM EDT